Newsletter Subject

⚡ The Small Biotech Scaring Big Pharma

From

capitalsmartstrategies.com

Email Address

open@expert.CapitalSmartStrategies.com

Sent On

Fri, May 10, 2024 03:15 PM

Email Preheader Text

It really is the biggest "hidden" opportunity on Wall Street. ? Dear Fellow Investor, It really is

It really is the biggest "hidden" opportunity on Wall Street. [Capital Smart Strategies](   Dear Fellow Investor, It really is the biggest "hidden" opportunity on Wall Street. [Click here]( You see, while everyone else has been focused on crypto and pot stocks, we've been focused where no one else was looking: the biotech sector. As a result, we've had a different biotech stock taken over every 56 days... I'm truly grateful to be able to share my passion for biotech stocks with you (and I hope you've made some good money!). But today, I thought I'd take a moment to discuss where this big merger wave is coming from. It all started back in 1990 with the Human Genome Project (HGP), the international scientific research project dedicated to mapping the human genome. One of the many big benefits of the HGP was that for the first time ever, scientists were able to identify mutations linked to different forms of cancer. It wasn't long before they began to design new medications to address them. Now here's where it gets interesting... 75% of Cancer Drugs are Old Chemical Drugs Currently, 75% of all drugs to treat cancer are old chemical drugs. For example, the most popular drug to treat Leukemia is Cytarbine. Well guess what? Cytarbine was patented in 1960! A lot has changed in medicine since 1960! That's why the side effects are horrendous. They include bone marrow suppression, vomiting, diarrhea, liver problems, rash, ulcer formation in the mouth, and bleeding. Many of you know first-hand what I'm talking about. Going through chemo yourself or watching a loved one go through it is brutal. Absolutely brutal. This is what they mean by the expression "the chemo will get you before the cancer does." The good news is that that's now the "OLD WAY" of fighting cancer. Ever since the HGP, scientists have begun to develop molecular profiles of both the patient and the actual cancer. And they've been creating treatments based on those profiles. Precision-medicine. Now we have a whole "NEW WAY" of fighting cancer. [Find out the Small Biotech scaring Big Pharma ]( How does that make this such a golden opportunity for takeover investors? It's simple... Worldwide spending on cancer therapies was about $140 billion in 2018, according to the American Association of Cancer Research. $105 billion, or 75% of that money was spent on the "OLD WAY" of treating cancer. $35 billion, or 25%, was spent on the "NEW WAY" of treating cancer. Well guess what? Those numbers are about to flip. It won't be long before 75% of all money for cancer therapies are spent on the "NEW WAY" of fighting cancer. It gets even better... Right now, Big Pharma (Pfizer, Eli Lilly, Glaxo, Bristol Meyers, etc) owns the "OLD WAY" oncology market. They haveit locked down. But a new crop of small biotech companies is developing the "NEW WAY" oncology market. The Small Biotech Scaring Bristol Meyers One tiny biotech invented a breakthrough Leukemia treatment. This new medicine targets patients by their genetic profile. This new discovery threatens Big Pharma companies Bristol Meyers and Novartis. That makes this small biotech our top takeover target this month. [Find out the rest of the story here ]( And guess what? Big Pharma has to buy Small Pharma if they want to keep their place in the market. That's why we've been able to rack up such great gains riding this wave - Pfizer bought "NEW WAY" firm Array Biopharma last month for $48 a share, a 144% gain from our recommended price of $18.90. Glaxo bought "NEW WAY" firm Tesaro in March for $74.96, a 93% gain from our recommended price of $38.41. Eli Lilly bought "NEW WAY" firm Loxo Oncology in January for $234.66, a 78% gain from our recommended price of $131.02. Illumina bought "NEW WAY" diagnostic firm Pacific Biosciences for $8, an 82% gain from our recommended price of $4.38. Want to know the next "NEW WAY" cancer drug company we think gets acquired? [Find out the Small Biotech scaring Big Pharma ]( "The Buck Stops Here" [Dylan Jovine] Dylan Jovine Chairman Behind the Markets 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   Capital Smart Strategies is presented by Inception Media, LLC. Inception Media, LLC values your comments and questions. Please note that Inception Media, LLC is not authorized to offer personalized financial advice. This email does not constitute financial advice, and any investment decisions are entirely your responsibility. Feel free to contact us support@capitalsmartstrategies.com 600 N Broad St Ste 5 PMB 1 Middletown, DE 19709 Inception Media, LLC. All rights reserved. [Signature] [Contact Us]( [Capital Smart Strategies]( [Unsubscribe](

Marketing emails from capitalsmartstrategies.com

View More
Sent On

26/05/2024

Sent On

26/05/2024

Sent On

26/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Sent On

25/05/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2024 SimilarMail.